Veeva(VEEV) - 2026 Q1 - Quarterly Report

Financial Performance - Total revenues for the three months ended April 30, 2025, were $759,043,000, representing a 16.7$650,345,000 in the same period of 2024[18]. - Subscription services revenue increased to $634,768,000, up 18.9$533,955,000 year-over-year[18]. - Net income for the quarter was $228,190,000, a 41.1$161,664,000 in the prior year[18]. - Operating income rose to $233,732,000, reflecting a 50.5$155,172,000 in the same quarter of 2024[18]. - The company reported a gross profit of $585,219,000, which is a 22.8$476,461,000 in the same quarter last year[18]. - Net cash provided by operating activities was $877,158,000, compared to$763,516,000 for the same period in 2024, marking a 14.9% increase[24]. - The company generated net income of $714 million for the fiscal year ended January 31, 2025, representing a 35.7$526 million in 2024[80]. Assets and Equity - Cash and cash equivalents at the end of the period were $1,964,982,000, up from$1,118,785,000 at the beginning of the year[15]. - Total assets increased to $7,765,077,000, compared to$7,339,756,000 as of January 31, 2025[15]. - Stockholders' equity grew to $6,211,098,000, up from$5,832,373,000 at the end of the previous quarter[15]. - Veeva's total available-for-sale securities amounted to $4,103,435 thousand as of April 30, 2025, with a gross unrealized gain of$31,083 thousand and unrealized losses of $2,050 thousand[32]. Expenses - Research and development expenses were$184,033,000, an increase of 13.1% from $162,711,000 in the prior year[18]. - Sales and marketing expenses increased slightly to$98,628 thousand, a 1% rise from $97,301 thousand, driven by higher employee compensation costs[107]. - General and administrative expenses increased by 12$68,826 thousand, primarily due to a $10 million rise in employee compensation-related costs[109]. Tax and Income Per Share - The effective tax rate for the three months ended April 30, 2025, was 23.6$1.40 for the three months ended April 30, 2025, up from $1.00 in the same period of 2024, a 40$459,467 thousand in revenues for the three months ended April 30, 2025, a 20.4% increase from $381,599 thousand in 2024[71]. - R&D Solutions accounted for 54% of total revenues for the three months ended April 30, 2025, while Commercial Solutions accounted for 46%[79]. - The company served 1,477 customers as of January 31, 2025, an increase from 1,432 customers in 2024[81]. Risks and Challenges - The company faces risks related to cybersecurity, including potential breaches that could harm customer trust and lead to significant liabilities[153]. - The markets for the company's solutions are highly competitive, with significant competition from firms like Salesforce and IQVIA[160]. - The company is subject to changing laws and regulations, which may impose additional compliance costs and liabilities[158]. - The company faces risks related to international operations, including regulatory, economic, and political challenges[171]. Compliance and Regulatory Environment - Compliance with complex regulations in the life sciences industry is essential; failure to comply could lessen demand for solutions and expose the company to significant claims[193]. - Increasingly complex data protection regulations, such as the EU GDPR, impose significant obligations and potential penalties for non-compliance, affecting operational costs[199]. - The company anticipates ongoing evolution of privacy and data protection laws, which will require continuous compliance efforts and could lead to increased operational complexity[201]. Strategic Initiatives - The company announced the launch of Veeva AI, integrating AI across major application areas, which may introduce new risks and challenges affecting adoption[207]. - The company expects R&D Solutions revenues to increase as a percentage of total revenues in the future[79].